Appendix 3Y - Change of Director’s Interest Notice
CLINUVEL has entered a formal collaboration with four of the world’s leading...
Read More
CEO letter to shareholders
Melbourne, Australia, 19 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
CLINUVEL Confirms AGM Date
Melbourne, Australia, 13 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
CLINUVEL Vitiligo Expert Panel
CLINUVEL has entered a formal collaboration with four of the world’s leading...
Read More
SCENESSE® in adolescent EPP study
Melbourne, Australia, 5 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
Investor Webinar transcript
Melbourne, Australia, 30 August 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
Appendix 4G and Corporate Governance Statement
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Dividend/Distribution – CUV
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Appendix 4E & Annual Report
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Annual Results – Investor Webinar
Melbourne, Australia, 28 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Technical Note: DNA Damage and Repair
This Technical Note provides further detail on the current standards of care...
Read More
Afamelanotide Significantly Reduces DNA Damage in a Healthy Population
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read More
SCENESSE® applied under five-year Veterans Affairs contract
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read More
CLINUVEL secures IP for melanocortins to treat central nervous system disorders
CLINUVEL has secured a family of patents and patent applications relating to...
Read More